Treating screwworm: Why an OTC generic is now the frontline

Written by The Life Science Feed Editorial Team · Published 22 July 2026 · Edited by Mara Voss

> New World screwworm (Cochliomyia hominivorax) infestations pose a significant, often fatal, threat to domestic animals, particularly in regions where the parasite is endemic or re-emerging. Rapid, accessible treatment is critical to prevent widespread morbidity and mortality in affected populations. The FDA's recent Emergency Use Authorization (EUA) for a generic over-the-counter (OTC) drug offers a new, immediate avenue for managing these parasitic infections in dogs and cats.

KEY TAKEAWAYS

- The Pivot: A generic, over-the-counter drug is now authorized for emergency use against New World screwworm in companion animals.
- The Data: The authorization is based on established efficacy and safety profiles of the active pharmaceutical ingredient.
- The Action: Clinicians and pet owners in affected areas now have immediate access to a readily available treatment option.

New World screwworm, a notorious obligate parasite, infests open wounds in warm-blooded animals, including dogs and cats, leading to severe tissue destruction and often death if left untreated. The larvae feed on living tissue, distinguishing them from most other myiasis-causing flies that feed on necrotic tissue. This aggressive feeding behavior necessitates prompt intervention to save the animal and prevent further spread of the parasite.

The FDA issued an Emergency Use Authorization for a generic, over-the-counter formulation of ivermectin, specifically for the treatment of New World screwworm infestations in dogs and cats. This authorization provides a critical tool for veterinarians and animal owners, particularly in areas experiencing outbreaks or where veterinary access is limited. The decision reflects the urgent public health and animal welfare need to control this destructive parasite.

The Basis for Emergency Authorization

The EUA for generic ivermectin relies on the extensive existing data regarding the drug's efficacy and safety in treating parasitic infections in animals. Ivermectin, a macrocyclic lactone, disrupts the nervous system of invertebrates, leading to paralysis and death of the parasite. Its broad-spectrum antiparasitic activity has made it a cornerstone in veterinary medicine for decades.

While specific clinical trials for this exact generic formulation against New World screwworm under an EUA framework were not conducted, the authorization leverages the established pharmacological profile and clinical history of ivermectin. The drug has a well-understood mechanism of action against various arthropods and nematodes, including

those closely related to Cochliomyia hominivorax. This foundational knowledge supports its use in an emergency context where immediate action is paramount.

The formulation is intended for topical application, allowing for direct treatment of infested wounds. This method minimizes systemic exposure while delivering a high concentration of the active ingredient to the site of infestation. Dosing recommendations are based on body weight, consistent with standard veterinary practice for ivermectin. Clinicians should consult the product's prescribing information for precise application guidelines and contraindications, particularly concerning breeds known for ivermectin sensitivity.

Practical Implications for Clinicians

The availability of an OTC generic ivermectin under EUA simplifies access to treatment, bypassing the need for a veterinary prescription in emergency scenarios. This is particularly relevant in rural or remote areas where veterinary services may be scarce, or during large-scale outbreaks where rapid deployment of treatment is essential. Pet owners can now obtain and administer the treatment more quickly, potentially reducing the severity of infestations and improving outcomes.

But, veterinarians still play a crucial role in diagnosis and guiding appropriate use. Misdiagnosis of screwworm or improper application of the drug could lead to treatment failure or adverse effects. Clinicians should educate pet owners on accurate identification of screwworm larvae, proper wound management, and the correct administration of the product. The Oxford Handbook of Infectious Diseases and Microbiology offers a useful reference for understanding parasitic life cycles and treatment principles.

The open-label nature of an EUA means that post-market surveillance will be critical to monitor real-world efficacy and any unforeseen adverse events. The FDA will collect data on outcomes, which will inform future regulatory decisions regarding permanent approval or modifications to the EUA. This ongoing monitoring ensures that the benefits continue to outweigh the risks in the field.

The trial was not powered to detect differences in efficacy across various dog or cat breeds, and that gap matters. While ivermectin is generally safe, certain breeds, such as Collies and Australian Shepherds, carry a mutation in the ABCB1 (MDR1) gene that makes them highly sensitive to ivermectin, even at therapeutic doses. Clinicians must advise owners of these breeds to exercise extreme caution and consider veterinary consultation before administering the OTC product. The potential for neurotoxicity in sensitive individuals remains a significant concern.

> **CLINICAL IMPLICATIONS**
>
> The FDA's Emergency Use Authorization for generic ivermectin against New World screwworm provides a pragmatic solution to an acute problem. This move acknowledges the immediate need for accessible treatment in situations where the parasite poses a rapid, severe threat to animal populations. It is a testament to regulatory agility when faced with a clear and present danger.
>
> Clinicians will find this authorization a double-edged sword. While it empowers pet owners with direct access to a vital medication, it also places a greater onus on veterinarians to provide clear, concise guidance on diagnosis and safe administration. The potential for misuse or adverse reactions, particularly in ivermectin-sensitive breeds, means education remains paramount.
>
> The industry will likely see increased demand for this generic formulation, but the EUA framework means

> manufacturers must continue to engage with regulatory bodies for full approval. This interim measure is not a substitute for comprehensive clinical development, but it does highlight the value of established, off-patent compounds in emergency preparedness.
>
> The unanswered question remains how effectively this OTC availability will translate into reduced screwworm incidence without direct veterinary oversight. Public health campaigns and clear labeling will be essential to maximize benefit and minimize harm, particularly regarding appropriate wound care and breed-specific precautions.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. FDA. FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats. Accessed Jul 2026. http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-generic-over-counter-drug-treat-new-world-screwworm-d

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com